RESUMEN
Rapid diagnostic testing at the site of the patient is essential when a fully equipped laboratory is not accessible. To maximize the impact of this approach, low-cost, disposable tests that require minimal user-interference and external equipment are desired. Fluid transport by capillary wicking removes the need for bulky ancillary equipment to actuate and control fluid flow. Nevertheless, current microfluidic paper-based analytical devices based on this principle struggle with the implementation of multistep diagnostic protocols because of fabrication-related issues. Here, 3D-printed microfluidic devices are demonstrated in a proof-of-concept enzyme-linked immunosorbent assay in which a multistep assay timeline is completed by precisely engineering capillary wetting within printed porous bodies. 3D printing provides a scalable route to low-cost microfluidic devices and obviates the assembly of discrete components. The resulting rapid and seamless transition between digital data and physical objects allows for rapid design iterations, and opens up perspectives on distributed manufacturing.
Asunto(s)
Dispositivos Laboratorio en un Chip , Impresión TridimensionalRESUMEN
The lab-on-a-chip (LOC) field has witnessed an excess of new technology concepts, especially for the point-of-care (POC) applications. However, only few concepts reached the POC market often because of challenging integration with pumping and detection systems as well as with complex biological assays. Recently, a new technology termed SIMPLE was introduced as a promising POC platform due to its features of being self-powered, autonomous in liquid manipulations, cost-effective and amenable to mass production. In this paper, we improved the SIMPLE design and fabrication and demonstrated for the first time that the SIMPLE platform can be successfully integrated with biological assays by quantifying creatinine, biomarker for chronic kidney disease, in plasma samples. To validate the robustness of the SIMPLE technology, we integrated a SIMPLE-based microfluidic cartridge with colorimetric read-out system into the benchtop Creasensor. This allowed us to perform on-field validation of the Creasensor in a single-blind study with 16 plasma samples, showing excellent agreement between measured and spiked creatinine concentrations (ICC: 0.97). Moreover, the range of clinically relevant concentrations (0.76-20 mg/dL), the sample volume (5 µL) and time-to-result of only 5 min matched the Creasensor performance with both lab based and POC benchmark technologies. This study demonstrated for the first time outstanding robustness of the SIMPLE in supporting the implementation of biological assays. The SIMPLE flexibility in liquid manipulation and compatibility with different sample matrices opens up numerous opportunities for implementing more complex assays and expanding its POC applications portfolio.